- Home
- QSI vs SGMT Comparison
QSI vs SGMT Comparison
Compare QSI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QSI | SGMT |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 238.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | QSI | SGMT |
|---|---|---|
| Price | $1.27 | $5.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.63 | ★ $29.71 |
| AVG Volume (30 Days) | ★ 5.2M | 556.0K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,177,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $159.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.20 | N/A |
| 52 Week Low | $0.95 | $1.73 |
| 52 Week High | $4.63 | $11.41 |
Technical Indicators
Market Signals| Indicator | QSI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 34.54 |
| Support Level | $1.07 | $5.43 |
| Resistance Level | $1.34 | $6.11 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 72.22 | 8.00 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.